[
  {
    "symbol": "CPIX",
    "price": 3.32,
    "marketCap": 49670852,
    "beta": -0.293,
    "lastDividend": 0,
    "range": "1.04-7.25",
    "change": 0.72,
    "changePercentage": 27.69231,
    "volume": 251850,
    "averageVolume": 41420,
    "companyName": "Cumberland Pharmaceuticals Inc.",
    "currency": "USD",
    "cik": "0001087294",
    "isin": "US2307701092",
    "cusip": "230770109",
    "exchangeFullName": "NASDAQ Global Select",
    "exchange": "NASDAQ",
    "industry": "Drug Manufacturers - Specialty & Generic",
    "website": "https://www.cumberlandpharma.com",
    "description": "Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, rheumatology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of chronic and acute constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections. It also develops RediTrex injection for the treatment of active rheumatoid, juvenile idiopathic, and severe psoriatic arthritis, as well as disabling psoriasis. In addition, the company is developing ifetroban, a product candidate that is in phase II clinical trial for the treatment of aspirin-exacerbated respiratory disease, systemic sclerosis, and duchenne muscular dystrophy; and has completed phase II clinical trial for the treatment of hepatorenal syndrome and portal hypertension. Further, it develops a clinical program for the use of ifetroban to treat progressive fibrosing interstitial lung diseases; and a product candidate that is in Phase II clinical trial for cholesterol reducing agent to use in the hospital setting. The company was incorporated in 1999 and is headquartered in Nashville, Tennessee.",
    "ceo": "A. J. Kazimi MBA",
    "sector": "Healthcare",
    "country": "US",
    "fullTimeEmployees": "91",
    "phone": "615 255 0068",
    "address": "2525 West End Avenue",
    "city": "Nashville",
    "state": "TN",
    "zip": "37203",
    "image": "https://images.financialmodelingprep.com/symbol/CPIX.png",
    "ipoDate": "2009-08-11",
    "defaultImage": false,
    "isEtf": false,
    "isActivelyTrading": true,
    "isAdr": false,
    "isFund": false
  }
]